Welcome to our dedicated page for Akoya Biosciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya Biosciences stock.
Akoya Biosciences, Inc. (AKYA), known as The Spatial Biology Company®, generates news that spans technology developments, collaborations, financial reporting, and corporate transactions. Company announcements emphasize its single-cell imaging and spatial proteomics platforms, which are used to phenotype cells with spatial context and study how they organize and interact in disease. News items often describe how Akoya’s PhenoCode™ Panels, PhenoCycler®, Phenor® Fusion, and Phenor HT instruments are applied across discovery, translational, and clinical research.
Investors and researchers following AKYA-related news will find updates on spatial biology and proteomics initiatives, including large-scale projects and partnerships. Recent releases highlight collaborations such as the Cancer Grand Challenges-funded study using PhenoCycler-Fusion, the SUPER study with the Singapore Translational Cancer Consortium leveraging the IO60 panel to investigate PD-1 immunotherapy response, and the Enable Medicine Pan-Cancer Atlas built on Akoya’s PhenoCycler-Fusion and IO60 technologies. These stories illustrate how Akoya’s platforms are integrated into biomarker discovery, drug development, and precision oncology efforts.
News coverage has also included financial results and operational updates, such as quarterly revenue composition, changes in operating expenses, and growth in the installed base of instruments and publications citing Akoya’s technology. In addition, corporate and capital markets news has been prominent, particularly the Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and subsequent shareholder and activist responses to that transaction.
Following the completion of the merger on July 8, 2025, Akoya became a wholly owned subsidiary of Quanterix, and its common stock was removed from listing on Nasdaq. The AKYA news stream therefore serves as a historical archive of Akoya’s activities as an independent public company, covering its evolution in spatial biology, its collaborations, and the steps leading to its acquisition by Quanterix.
Akoya Biosciences (Nasdaq: AKYA) will release its first quarter 2021 financial results after market close on May 18, 2021. Management will discuss these results during a conference call scheduled for 5:00 p.m. ET. Investors can participate by calling (833) 562-0146 domestically or (661) 567-1226 internationally, using Conference ID: 7824008. A live and archived webcast will also be available on the Akoya website.
Akoya is known for its spatial biology solutions, including CODEX® and Phenoptics™ platforms, which allow researchers to explore cell interactions in health and disease.
Akoya Biosciences (Nasdaq: AKYA) has launched its Imaging Innovators Network (I²), inviting researchers to apply innovative uses for the CODEX® system. This initiative aims to push the frontiers of spatial biology through open collaboration and cutting-edge applications. Initially, 10 researchers will be selected to leverage the CODEX system's capabilities, which can analyze over 40 biomarkers in tissue, enhancing disease research. Applications are open until July 9, 2021.
On May 3, 2021, Akoya Biosciences (Nasdaq: AKYA) completed its initial public offering (IPO) by issuing 7,567,000 shares at $20 per share, raising approximately $151 million. This offering included the underwriters' option to purchase an additional 987,000 shares. Akoya specializes in single-cell imaging solutions, utilizing its CODEX® and Phenoptics™ platforms to enhance research in disease progression and treatment response. DLA Piper facilitated this transaction, leveraging its expertise in capital markets and life sciences.
Akoya Biosciences, Inc. (Nasdaq: AKYA) successfully closed its initial public offering (IPO) of 7,567,000 shares at $20.00 per share, raising approximately $151.3 million in gross proceeds. The offering included the full exercise of underwriters' option to purchase an additional 987,000 shares. Trading began on April 16, 2021, on The Nasdaq Global Select Market under the symbol "AKYA." J.P. Morgan, Morgan Stanley, Piper Sandler, and Canaccord Genuity acted as joint book-running managers. The registration statement for the offering was approved by the SEC on April 15, 2021.
Akoya Biosciences has announced the pricing of its initial public offering (IPO) of 6,580,000 shares at $20.00 each, raising approximately $131.6 million before expenses. The offering includes a 30-day option for underwriters to purchase up to 987,000 additional shares. Trading on the Nasdaq under the ticker symbol 'AKYA' is expected to commence on April 16, 2021, with closure anticipated by April 20, 2021, pending usual conditions. J.P. Morgan, Morgan Stanley, Piper Sandler, and Canaccord Genuity are the joint book-running managers for this offering.